Richard Moore | Gynecologic Oncology | Leadership in Research Excellence Award

Published on by Academic Awards

Dr. Richard Moore | Gynecologic Oncology | Leadership in Research Excellence Award

University of Rochester | United States

Dr. Richard Moore is a distinguished leader in gynecologic oncology, renowned for his pioneering research, academic excellence, and leadership in translational medicine. He earned degrees in mechanical and industrial engineering before pursuing biology and obtaining his MD from the University of Alberta. His postgraduate training at Eastern Virginia Graduate School of Medicine and fellowship at Brown University established his foundation in women’s oncology. Over his illustrious career, Dr. Richard Moore has held prestigious roles, including Director of the Molecular Therapeutics Laboratory and Center for Biomarkers and Emerging Technology at Brown University, and currently serves as Chief of Gynecologic Oncology and Director of the Targeted Therapeutics Laboratory for Gynecologic Cancers at the University of Rochester Medical Center. A tenured professor, he has contributed significantly to advancing targeted therapeutics, biomarker discovery, and patient-centered oncology care. His work has earned numerous awards, international recognition, and over 8,037 citations from 135 publications and an impressive h-index of 39.

Profile: Scopus

Featured Publications

  • OVARIO Investigators, & Moore, R. G. (2025). A phase 2 trial of niraparib plus bevacizumab maintenance therapy following first-line platinum-based chemotherapy with bevacizumab in advanced ovarian cancer: Final analysis and overall survival results from OVARIO. Gynecologic Oncology.

  • NRG Oncology, & Moore, R. G. (2025). Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: Overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial. Nature Medicine.

  • Moore, R. G., et al. (2025). First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: A randomized, open-label, phase III trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology.

  • Moore, R. G., et al. (2025). Endometrioid adenocarcinoma of the colon arising from rare malignant transformation of extra-gonadal endometrioma. Gynecologic Oncology Reports.

  • Moore, R. G., et al. (2025). Estrogen therapy in patients with gynecologic cancer: A survey of gynecologists and oncologists in the United States. Menopause.